Work

Supplementary Fig. S1 from Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Fig. S1 - PDF file 83K, Time profiles for estimated change relative to baseline in (A) heart rate and (B) Fridericia-corrected QT interval

DOI: 10.1158/1078-0432.22449279

Authors: Cristiana Sessa, Patricia Lorusso, Anthony Tolcher, Françoise Farace, Nathalie Lassau, Angelo Delmonte, Antonio Braghetti, Rastislav Bahleda, Patrick Cohen, Marie Hospitel, Christine Veyrat-Follet, Jean-Charles Soria

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361819713

Cites:

Cited by:

Related to: 10